Prevention and/or treatment of neurodegenerative disease
A method for the prevention and/or treatment of dementia in a human subject; the method comprising the step of administering an effective amount of a composition comprising at least one carotenoid selected from the group consisting of lutein, zeaxanthin and meso-zeaxanthin; and a composition comprising at least one omega-3 fatty acid.
1. A method for preventing or retarding the progression of cognitive impairment in a human subject exhibiting cognitive impairment due to dementia, the method comprising the step of administering an effective amount of a composition comprising each of lutein, zeaxanthin and meso-zeaxanthin; and a composition comprising at least one omega-3 fatty acid, wherein the human subject to be treated has a mini mental state examination (MMSE) score of 25 or less.
2. The method according to claim 1 , wherein a single administered composition comprises each of lutein, zeaxanthin, meso-zeaxanthin and at least one omega-3 fatty acid.
3. The method according to claim 1 , wherein the said at least one omega-3 fatty acid is docosahexaenoic acid.
4. The method according to claim 1 , wherein the said at least one omega-3 fatty acid is provided in the composition as a fish oil.
5. The method according to claim 1 , wherein the said at least one omega-3 fatty acid comprises at least two omega-3 fatty acids.
6. The method according to claim 1 , wherein the omega-3 fatty acid-containing composition comprises docosahexaenoic acid and eicosapentaenoic acid.
7. The method according to claim 1 , wherein the said at least one omega-3 fatty acid is provided as the free acid, as a salt or as a triglyceride.
8. The method according to claim 7 , wherein the salt comprises a monocation.
9. The method according to claim 7 , wherein the salt comprises a metal monocation.
10. The method according to claim 1 , wherein the composition/s is/are administered orally to the subject at least three times a week.
11. The method according to claim 1 , wherein the composition/s is/are administered to the subject daily.
12. The method according to claim 1 , wherein the composition/s is/are in unit dose form.
13. The method according to claim 12 , wherein each unit dose of composition comprises about 10 mg meso-zeaxanthin, about 10 mg lutein, about 2 mg zeaxanthin, and fish oil containing said at least one omega-3 fatty acid.
14. The method according to claim 12 , wherein each unit dose of composition comprises about 15 mg meso-zeaxanthin, about 5 mg lutein, about 1 mg zeaxanthin, and fish oil containing said at least one omega-3 fatty acid.
15. The method according to claim 12 , wherein each unit dose of the composition comprises between about 20 mg and about 2 grams of docosahexaenoic acid.
16. The method according to claim 12 , wherein each unit dose of composition comprises about 1 gram of fish oil containing said at least one omega-3 fatty acid.
17. The method according to claim 1 , wherein the composition/s further comprise one or more of the following: acidity regulators; anticaking agents selected from the group consisting of sodium aluminosilicate, calcium or magnesium carbonate, calcium silicate, sodium and potassium ferricyanide; antioxidants selected from the group consisting of vitamin E, vitamin C, and polyphenols; colorings selected from the group consisting of artificial colorings FD&C Blue No. 1, Blue No. 2, Green No. 3, Red No. 40, Red No. 3, Yellow No. 5 and Yellow No. 6; and natural colorings selected from the group consisting of caramel, annatto, cochineal, betanin, turmeric, saffron, and paprika; color retention agents; emulsifiers; flavours; flavour enhancers; preservatives; stabilizers; sweeteners and thickeners.
18. The method according to claim 1 , wherein the composition/s is/are in the form of a tablet or capsule.
19. The method according to claim 1 , wherein the subject consumes the composition/s on a daily basis over a period of at least 12 months.
20. The method according to claim 1 , comprising use of a composition consisting essentially of lutein, zeaxanthin, meso-zeaxanthin, at least one omega-3 polyunsaturated fatty acid or corresponding salt or triglyceride, and a diluent, carrier or excipient.
21. The method according to claim 20 , wherein the omega-3 polyunsaturated fatty acid or corresponding salt or triglyceride is DHA or a salt or triglyceride of DHA.
22. The method according to claim 1 , wherein the method comprises daily oral administration of a unit dose form composition comprising each of lutein; zeaxanthin; meso-zeaxanthin; and DHA and/or EPA, in preventing or retarding the progression of cognitive impairment in a subject already exhibiting one or more symptoms of Alzheimer's disease prior to administration of the composition.